Physician profile
Jason Chu
NPI 1972521060
$158,591.33
in general payments reported to CMS, 2019-2025
22 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $19K · 2021: $40K · 2022: $42K · 2023: $22K · 2024: $18K · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $6,785 · Travel and Lodging: $4,448 · Consulting Fee: $2,000 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,248.00 |
| Food and Beverage | $6,784.91 |
| Travel and Lodging | $4,448.28 |
| Consulting Fee | $2,000.00 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $48,283.79 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $44,481.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Mallinckrodt Hospital Products INC. | $25,456.62 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,408.97 | 2019-2025 | Ofev, Jascayd |
| Electromed, INC. | $15,014.26 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $8,847.00 | 2019-2022 | |
| Inspire Medical Systems, INC. | $177.10 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $161.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $92.84 | 2019 | |
| Genzyme Corporation | $92.05 | 2022 | |
| Vifor Pharma, INC. | $89.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $79.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.02 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.49 | 2019-2021 | |
| Insmed, INC. | $48.40 | 2021-2025 | Brinsupri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $46.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $43.13 | 2022 | |
| Monaghan Medical Corporation | $33.44 | 2019 | |
| Rigel Pharmaceuticals, INC. | $26.46 | 2021 | |
| Mallinckrodt Enterprises LLC | $25.75 | 2019 | |
| Breathe Technologies, INC. | $24.62 | 2019 | |
| Mylan Specialty L.P. | $24.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.